SunTrust analyst Peter Lawson initiated Deciphera (DCPH) with a Buy rating and a price target of $60, citing the company's differentiated position of developing kinase inhibitors that can hit multiple mutations, potentially better controlling cancer. Given its wholly owned pipeline of 3 clinical drugs, the lead of which is targeting Gastrointestinal stromal tumor in two phase 3 trials by the second half of this year, the analyst recommends that investors acquire shares ahead of those readouts. Lawson further states that other kinase targeting peer companies such as Loxo Oncology (LOXO), Blueprint Medicines (BPMC), and Mirati Therapeutics (MRTX) also point to significant upside amid clinical validation progress.